Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Imunon, Inc. (IMNN) entered an Exchange Agreement with Streeterville Capital, LLC under which $1,200,000 of principal under its A-1 Note, together with accrued and unpaid interest, will be exchanged for 120 shares of Series B preferred stock at $10,000 per share. Upon the exchange, Imunon’s obligations under the A-1 Note will be reduced by the principal and interest exchanged; the note otherwise remains in full force and effect.
Imunon designated 200 Series B shares, effective upon filing. Each share has a $12,000 stated value and accrues an 8% annual return, payable in cash or additional Series B shares; it is not convertible into common stock or any other class or series of Imunon stock. Subject to the designation’s terms, Imunon may redeem all or part of the outstanding Series B shares from holders of Series A preferred stock by paying cash equal to 110% of the applicable liquidation amount. Following an event of default, the return would increase by 15% per year. Holders have no voting rights except on matters materially and adversely affecting Series B rights or as required by law.
Imunon, Inc. (IMNN) Executive Chairman of Board Michael H. Tardugno received 7,169 common shares on September 25, 2026, as stock granted in lieu of cash for base salary. The reported price was $1.4100 per share. His direct holdings after the award were 103,921 shares; a separate holding line lists 4,622 shares held by an IRA.
Imunon, Inc. President and CEO and director Stacy Lindborg acquired 6,697 shares of common stock on September 25, 2026, as stock granted in lieu of cash for a portion of base salary. The reported price was $1.4100 per share. Her direct holdings after the award were 113,197 shares; she also reported 778 shares indirectly held by a 401(k) Plan.
Imunon, Inc. Chief Medical Officer Douglas Vincent Faller acquired 4,390 shares of common stock on September 25, 2026, as stock granted in lieu of cash for a portion of base salary. The reported price was $1.41 per share, and Faller held 45,678 shares directly after the award.
Imunon, Inc. (symbol: IMNN) is the issuer of record for a Form 4 filing submitted to the SEC. Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. (IMNN) reported that Executive Chairman of the Board Michael H. Tardugno received a grant of 5,824 shares of Common Stock on September 11, 2026 at $1.47 per share, issued as stock in lieu of cash for base salary. Following this award, he holds 95,699 shares directly and 4,622 shares indirectly through an IRA. No transactions were reported under a Rule 10b5-1 trading plan.
Imunon, Inc. (IMNN) reported that President and CEO Stacy Lindborg received a grant of 5,504 shares of common stock on September 11, 2026 as a grant, award, or other acquisition. The stock was granted in lieu of cash for a portion of base salary, at a reported value of $1.47 per share, bringing Lindborg’s directly held common stock to 105,580 shares. Lindborg also holds 778 shares indirectly through a 401(k) plan. No Rule 10b5-1 trading plan is reported for these transactions.
Imunon, Inc. (symbol: IMNN) is the issuer of record for a Form 4 filing submitted to the SEC. Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. (IMNN) reported that Chief Medical Officer Douglas Vincent Faller received an equity award on September 11, 2026. He was granted 4,211 shares of Common Stock at a value of $1.47 per share, issued in lieu of cash for a portion of his base salary, bringing his directly held stake to 41,288 shares. No transactions were reported under a Rule 10b5-1 trading plan.
Imunon, Inc. (symbol: IMNN) is the issuer of record for a Form 4 filing submitted to the SEC.
Imunon, Inc. (symbol: IMNN) is the issuer of record for a Form 4 filing submitted to the SEC.
Imunon, Inc. (symbol: IMNN) is the issuer of record for a Form 4 filing submitted to the SEC.